Physician profile
Mark Akira Takesuye
NPI 1558890210
$1,103.87
in general payments reported to CMS, 2019-2025
8 companies · $697 in 2025
The $697 reported for 2025 was more than what 90% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $56.04 · 2021: $30.89 · 2022: $126 · 2024: $22.09 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490 · Travel and Lodging: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.09 |
| Travel and Lodging | $229.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $601.29 | 2025 | Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $139.17 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.55 | 2019 | |
| Alcon Vision LLC | $113.15 | 2021-2025 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Allergan, INC. | $35.76 | 2019 | |
| Abb Con-Cise Optical Group LLC | $33.91 | 2019-2024 | Spectacle Lenses, Contact Lens |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Takesuye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.